Lantheus Holdings Inc., of North Billerica, Mass., has entered a strategic collaboration with Paris-based Carthera SAS for the use of its microbubbles in combination with Carthera’s investigational Sonocloud system. The implantable device is in development for the treatment of recurrent glioblastoma, a fast-growing brain tumor with a post-diagnosis median survival of just 15 months. The new deal furthers two of Lantheus’ strategic goals, finding new applications for its microbubbles and expanding its footprint in oncology.
Lantheus Holdings, of North Billerica, Mass., has entered a deal to acquire New York-based Progenics Pharmaceuticals Inc., which develops medicines and other technologies to target and treat cancer. "This transaction leverages our core capabilities, including proven commercial and operational expertise while diversifying our revenue stream by broadening our presence in emerging uses of radioisotopes in precision diagnostics as well as the exciting field of radiopharmaceuticals in oncology treatment," Lantheus President and CEO Mary Anne Heino said on a call related to the deal.
